01—Abstract
Summary
Summary of the 8-K filed November 15, 2024. Cited figures are marked; the original filing is the authoritative source.
On November 15, 2024, Boston Scientific (BSX) completed its acquisition of Axonics, Inc. (Nasdaq: AXNX), a medical technology company focused on devices for urinary and bowel dysfunction.
The cash purchase price of $71a per share implies an equity value of approximately $3.7 billion and an enterprise value of approximately $3.3 billion, net of roughly $0.4 billion in net cash and short-term investments as of September 30, 2024. The equity value is based on roughly 51.7 million fully diluted shares, including management incentives. Strategically, the deal lets Boston Scientific enter sacral neuromodulation, which management describes as a high-growth adjacency for its Urology business.
The product portfolio is intended to serve patients across life stages and incontinence severities. The filing is a routine event disclosure under Item 8.01, and the press release provides no quantitative revenue or growth figures for Axonics. For investors, management expects the deal to be immaterial to adjusted EPS in 2024 and 2025 and accretive thereafter.
On a GAAP basis, the deal is expected to be more dilutive because of amortization and acquisition-related charges. Key risks cited include integration of Axonics' operations, retention of business relationships after closing, and the realization of anticipated benefits.
02—Key points
Key Highlights
- Boston Scientific closed its acquisition of Axonics, Inc. on November 15, 2024, at $71 cash per share.
- Implied equity value is about $3.7 billion and enterprise value about $3.3 billion, net of roughly $0.4 billion in cash and short-term investments.
- Fully diluted share count of approximately 51.7 million shares, including management incentives, underlies the equity value.
- Deal is expected to be immaterial to adjusted EPS in 2024 and 2025 and accretive thereafter.
- On a GAAP basis, the transaction is expected to be more dilutive due to amortization expense and acquisition-related charges.
- Strategic entry into sacral neuromodulation, described as a high-growth adjacency for the Urology business.
- Key risks include successful integration of Axonics' operations and potential post-closing business disruption.
03—Questions
Frequently Asked Questions
How much is Boston Scientific paying for Axonics?
The purchase price is $71 per share in cash, equal to an equity value of about $3.7 billion and an enterprise value of about $3.3 billion. The enterprise value is net of roughly $0.4 billion in net cash and short-term investments as of September 30, 2024.
What does the acquisition do to Boston Scientific's earnings?
Management expects the deal to be immaterial to adjusted EPS in 2024 and 2025 and accretive thereafter. On a GAAP basis, it is expected to be more dilutive because of amortization expense and acquisition-related charges.
Why is Boston Scientific acquiring Axonics?
According to the press release, the acquisition lets Boston Scientific expand into sacral neuromodulation, which management calls a high-growth adjacency for its Urology business. It also broadens the company's portfolio for patients with different life stages and incontinence severities.
What are the main risks to the deal?
The forward-looking statements cite the ability to integrate Axonics' operations and achieve the anticipated benefits, as well as possible business disruptions with employees, customers and suppliers after announcement and closing. The filing does not quantify these risks.
04—Continue